SCHEMBL2197499

SCHEMBL2197499

Cc1nccc(N)c1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 6/20 0.39
NOS2 P35228 6/20 0.39
HTT P42858 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KDM4E B2RXH2 2/20 0.34
NOS1 P29475 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MTOR P42345 1/20 0.33
LOXL2 Q9Y4K0 2/20 0.32
NCF1 P14598 1/20 0.32
CYP2A6 P11509 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
LOX P28300 1/20 0.32
MBOAT4 Q96T53 2/20 0.31
HRH4 Q9H3N8 1/20 0.31
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31
USP7 Q93009 1/20 0.30
SYK P43405 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3-Methylpyridine SCHEMBL27689108 0.84 CYP2A6 (0.36) HTTHSD17B10KDM4ECYP2A6L3MBTL1
SCHEMBL1491842 0.78 NOS2 (0.42) NOS3NOS2HTTHSD17B10KDM4E
SCHEMBL17002575 0.78 CCR1 (0.38) NOS3NOS2LOXL2CYP2A6
Ammonia Solution, Strong SCHEMBL28037175 0.77 CCR1 (0.37) NOS3NOS2CYP2A6
SCHEMBL20347074 0.77 TRPV4 (0.34) NOS3NOS2CYP2A6
SCHEMBL1034691 0.75 NOS3 (0.39) NOS3NOS2HTTHSD17B10KDM4E
SCHEMBL17537336 0.75 NOTUM (0.39) NOS3NOS2CYP2A6L3MBTL1
SCHEMBL28272763 0.75 CYP2A6 (0.32) NOS3NOS2CYP2A6
Formamide SCHEMBL28001491 0.73 DRD1 (0.38) NOS3NOS2
SCHEMBL23074751 0.72 ALDH1A1 (0.33) NOS3NOS2HTTKDM4ELOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977342-B2 HCV inhibiting bi-cyclic pyrimidines TIBOTEC-VIRCO VIROLOGY BVBA (BE) 2011-07-12 US disclosed
EP-1608631-A4 BI-CYCLIC PYRIMIDINE INHIBITORS OF TGF BETA SCIOS INC (US) 2008-08-20 EP disclosed
US-20070155716-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-07-05 US disclosed
EP-1799218-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES Tibotec Pharmaceuticals Ltd. (IE) 2007-06-27 EP disclosed
US-7223766-B2 Bi-cyclic pyrimidine inhibitors of TGFβ SCIOS, INC. (US) 2007-05-29 US disclosed
WO-2006035061-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2006-04-06 WO disclosed
EP-1608631-A2 BI-CYCLIC PYRIMIDINE INHIBITORS OF TGF BETA SCIOS INC. (US) 2005-12-28 EP disclosed
US-20050004143-A1 Bi-cyclic pyrimidine inhibitors of TGFbeta SCIOS, INC. 2005-01-06 US disclosed
WO-2004087056-A2 BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ SCIOS INC. (US) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155716-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES UMPS, NUDT1, PNP NOS3 2764/4885NOS2 3067/4885HTT 4155/4885
US-20050004143-A1 Bi-cyclic pyrimidine inhibitors of TGFbeta TYMP, TYMS, TGFBR1 NOS3 2425/4885NOS2 2325/4885HTT 4457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.